telixpharmaceuticals

A Phase 1 Pharmacokinetic, Dosimetry, Safety, and Dose Optimization Study for a Single Dose of TLX090-Tx (153SmDOTMP) to Treat Metastatic Bone Pain

Description:

This is an open label, 2-part early phase study designed to evaluate the safety, pharmacokinetics, radiation dosimetry, and preliminary efficacy of TLX090-Tx in patients with painful bone metastases.

Contacts:

Jonathan Roger, MSc

jonathan.roger@telixpharma.com

579-366-1426 ext +1

Patient Education


Patient Education Not Yet Provided

Publications


Publications Not Yet Provided

Locations


United States 🇺🇸

TBD

United States

XCancer

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468